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Head and neck cancer
A B S T R A C T
Patients with mutated TP53 have been identified as having comparatively poor outcomes compared to those re-
taining wild-type p53 in many cancers, including squamous cell carcinomas of the head and neck (SCCHN). We
have examined the role of p53 in regulation of metabolism in SCCHN cells and find that loss of p53 function
determines the Warburg effect in these cells. Moreover, this metabolic adaptation to loss of p53 function creates
an Achilles’ heel for tumour cells that can be exploited for potential therapeutic benefit. Specifically, cells lacking
normal wild-type p53 function, whether through mutation or RNAi-mediated downregulation, display a lack of
metabolic flexibility, becoming more dependent on glycolysis and losing the ability to increase energy production
from oxidative phosphorylation. Thus, cells that have compromised p53 function can be sensitised to ionizing
radiation by pre-treatment with a glycolytic inhibitor. These results demonstrate the deterministic role of p53 in
regulating energy metabolism and provide proof of principle evidence for an opportunity for patient stratification
based on p53 status that can be exploited therapeutically using current standard of care treatment with ionising
radiation.
1. Introduction
One of the greatest challenges preventing the successful treatment of
cancer derives from difficulties in developing treatment strategies that
can distinguish tumour cells from normal and thus provide a substantial
therapeutic index. Since cancer is a genetic disease arising from the ac-
cumulation of critical somatic mutations, one way to distinguish cancer
cells from normal is through the detection of these somatic mutations.
Loss of p53 function is not only the single most common genetic
event in cancer, but is also linked with more aggressive disease and
poorer patient outcomes in many cancers [1,2]. This is particularly rel-
evant in cancers of the head and neck in which mutations of the TP53
gene are associated with the worst outcomes [3] and where TCGA has
reported a TP53 mutation frequency of over 80% in the majority of pa-
tients who are diagnosed with HPV negative squamous cell carcinomas
of the head and neck (SCCHN), making this the single most frequent ge-
netic event in this disease by a large margin [4].
Whilst many therapeutic approaches have been developed that try
to take advantage of oncogenic events such as translocations and acti
vation of signalling pathways promoting cell proliferation and survival,
loss of tumour suppressor function has proven largely refractory to at-
tempts to target therapeutic interventions [5].
This is not really surprising, since it is conceptually challenging to
envisage means to re-activate mutant gene function/s, but fortunately
the loss of tumour suppressor gene function in mutant cells frequently
creates other functional phenotypic consequences, and these are po-
tentially amenable to targeted intervention. Indeed, loss of p53 func-
tion leading, inter alia, to loss of induction of genotoxic checkpoint re-
sponses is a major component of the effectiveness of many conventional
chemotherapeutic agents (reviewed in Ref. [6]). The p53 protein co-or-
dinates a wide range of cellular processes, primarily through its func-
tion as a sequence specific transcriptional regulator [7,8], and recently,
it has become clear that p53 has several effects on cellular metabo-
lism. Amongst the first specific clues to this role were generated by
studies which identified firstly a novel p53-responsive gene encoded by
C12orf5, which was subsequently found to encode a fructose-2,6-bispho-
sphatase with roles in metabolic regulation and apoptosis (hence the
gene was named TIGAR, TP53 inducible glycolysis and apoptosis regu-
lator) [9,10].
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TIGAR catalyses the removal of phosphate from fructose-2,6-bispho-
phate generating fructose-6-phosphate, and in so doing promotes gluco-
neogenesis at the expense of glycolysis whilst also generating a key sub-
strate for the pentose phosphate pathway (PPP). Fructose-2,6-bisphos-
phate is a potent allosteric activator of phosphofructokinase-1 (PFK-1),
which catalyses one of the three major rate limiting steps in glycol-
ysis and the action of TIGAR thus directly suppresses glycolytic flux
[10,11]. In addition, studies have demonstrated that TIGAR also sup-
presses p53-mediated apoptosis, and that this is in part a result of the
enzymatic activity of TIGAR as a fructose-2,6-bisphosphatase which re-
sults in a reduction in ROS production with one mechanism being the
increased PPP flux and increased production of cellular reducing agents
[10,12]. Under hypoxic conditions, TIGAR also translocates to mito-
chondria where it binds to HK2 leading to increased phosphorylation of
glucose [13]. The combination of these activities of TIGAR would lead
to increased flux through the PPP.
As well as regulating TIGAR, p53 has been shown to have many
other impacts on cellular metabolism, ranging from suppressing glucose
transporter expression (GLUT-1 and GLUT-4), and promoting oxidative
respiration by up-regulating cytochrome c oxidase 2 (SCO2) even to hav-
ing a role in maintaining mitochondrial function and health (reviewed
in Ref. [14]).
Given the importance of p53 as a metabolic regulator, and loss of
p53 function as both a critical event in carcinogenesis and a determi-
nant of patient disease outcomes, it should hardly be surprising that p53
may provide a key link between carcinogenesis and metabolic adapta-
tions first described over 90 years ago by Warburg, Wind and Negelin
[15]. Studies by Myers and colleagues have shown a dependence on glu-
cose as a primary energy source in head and neck cancer cells and com-
paring HN30 (TP53 wild-type) and HN31 (TP53 C176F) cells as well as
using RNAi in these lines, they demonstrated that the extent of this de-
pendence was influenced by wild-type p53 expression levels and that
glucose dependence was greatest in cells that harboured a TP53 muta-
tion [16]. Further studies by this group have identified that the meta-
bolic phenotypes of TP53 wild-type and mutant cells are distinct, con-
firming the earlier studies of glucose dependence and identifying crit-
ical differences in respiration: with mutant cells displaying apparently
maximised use of oxidative phosphorylation and wild-type cells retain-
ing significant spare respiratory capacity. These studies also identified a
novel therapeutic opportunity based on the glycolytic dependence of the
SCCHN cells harbouring mutant TP53 [17].
A critical issue that arises from these studies is whether p53 in-
activation is associated, perhaps indirectly with the regulation of cell
metabolism, or whether there is a deterministic consequence of p53
function that causes differential metabolic phenotypes in mutant ver-
sus wild-type p53 cells. If the latter, then this might provide for more
robust opportunities for developing p53-based stratification of patients
for novel therapeutic strategies. To investigate this we have used iso-
genic cell lines with defined genetically manipulated TP53 status, in-
cluding p53 null, wild-type, and various loss of function, dominant
negative and gain of function mutants, to examine the role of p53 in
SCCHN metabolism and have found that p53 is deterministic in this
process. p53 status was further observed to be a predictor of cell me-
tabolism in a panel of (non-isogenic) SCCHN cells that either express
wild-type p53, or are null for p53 protein, or express a range of dif-
ferent mutants of p53 (comprising loss of function, dominant negative
activity and gain of function). This suggests that p53 status overrides
other genetic heterogeneities in conditioning cell metabolism and is
therefore a predictor of a clinically significant behaviour of SCCHN. We
also find that in absolute terms, loss of p53 function leads to a reduc-
tion in respiratory capacity, as well as increasing dependence on gly-
colysis. Moreover, this leads to increased sensitivity to ionizing radi-
ation (IR is a staple of SCCHN therapy) when combined with inhibi-
tion of glycolysis in TP53 mutant cells, but not in TP53 wild-type cells.
We also show that this is due to increased sensitivity to ROS in TP53
mutant cells. Thus we propose that since p53 determines this response,
future clinical trials stratifying patients based upon TP53 status, and
combining radiotherapy with inhibitors of specific metabolic pathways
should be prioritised in SCCHN.
2. Materials and methods
2.1. Cells and reagents
Parental UM-SCC (University of Michigan Squamous Cell Carcinoma)
cell lines (Supplementary Data Table 1), were kindly provided by
Prof. Thomas Carey, University of Michigan, MI, USA, and genetically
modified derivatives of UM-SCC-1 and UM-SCC-17A lines were kindly
provided by Prof. Jeffrey Myers, University of Texas MD Anderson Can-
cer Centre, TX, USA. Cell lines used include UM-SCC-1 (splice site mu-
tant rendering the cells null for p53 protein expression resulting in loss
of p53 function [LOF]) and derivatives of UM-SCC-1 that express ei-
ther wild-type p53, or a range of p53 missense mutants that display
gain of function (GOF); R175H, C176F and R282W, as well as patient
derived lines harbouring a range of mutants with different p53 pheno-
types: LOF; C242S, dominant negative activity (DNA); V157F, G245C
and H193R, and GOF; V157F and (albeit weakly) G245C [18–23]. The
identity of all cell lines was confirmed by STR profiling (Powerplex
from Promega, Southampton, UK) and comparison with previously pub-
lished analysis from the Carey group [24]. Isogenic cell lines differ-
ing only with respect to p53 expression were routinely monitored by
analysis of p53 expression levels as shown in Supplementary Data Fig.
1. Cells were maintained essentially as previously described [25]. Pri-
mary antibodies for western blot analysis were: anti-p53 (mouse mAb
DO-1, used at 3 μg/ml), anti-MDM2 (mouse mAb IF-2, used at 3 μg/
ml), anti-TIGAR (rabbit polyclonal antibody AB10545 used at 1 μg/ml)
supplied by Merck-Millipore, Watford, UK, anti-α-vinculin (mouse mAb
V9131, used at 1/100,000 dilution) supplied by Sigma-Aldrich, Poole,
UK. HRP-conjugated secondary antibodies used were sheep anti-mouse
antibody (NA931) at a 1/2500 dilution or donkey anti-rabbit anti-
body (NA934) at a 1/5000 dilution, both were supplied by GE Health-
care.Where indicated, cells were treated with or exposed to 1 μM stau-
rosporine (LC Laboratories, Woburn, MA, USA), 25 mM 2-deoxy-d-glu-
cose (2-DG), 25 mM N-acetylcysteine (NAC), 100 μM hydrogen peroxide
(H2O2), 2 μM UK5099 all from Sigma-Aldrich, Poole, UK, or ionizing ra-
diation (IR) delivered at room temperature using a CellRad cabinet X-ray
cell irradiator (Faxitron Bioptics LLC, Tucson, AZ, USA) calibrated to de-
liver 2 Gy/min of X-ray radiation.
2.2. Western blot analysis
Procedures for SDS-PAGE, western blotting and flow cytometric mea-
surement of apoptosis were performed as previously described [26–28].
Briefly, for western blots, protein lysates were resolved by SDS-PAGE
prior to transfer to nitrocellulose using a Bio-Rad Trans-Blot Turbo ac-
cording to the manufacturer's instructions. Blots were processed es-
sentially as described previously [29], probed with the indicated an-
tibodies and signals developed using Clarity™ Western ECL Substrate
(#1705060) and detected with a Bio-Rad Chemidoc MP.
2.3. Metabolic profile analysis
Metabolic studies were performed using Seahorse XF24 and XF96
analyzers (Seahorse Bioscience, Copenhagen, Denmark) to perform ei-
ther mitochondrial or glycolytic stress tests, essentially according to
the manufacturer's instructions. Experimental readouts are oxygen con-
sumption rate (OCR) in pmol/min and extracellular acidification rate
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Fig. 1. Wild-type p53 promotes increased oxidative phosphorylation and reduced glycolytic flux in head and neck cancer cells. A. Relative oxygen consumption rates (OCR) and
extracellular acidification rates (ECAR) were measured in mitochondrial and glycolytic stress tests respectively to ascertain levels of oxidative phosphorylation and glycolytic flux using a
Seahorse XF24 analyser for representative p53 wild-type (UM-SCC-17as) and mutant (UM-SCC-5) cell lines. Note that similar profiles with respect to p53 status are observed in all lines
(Supplementary Data Fig. 2). Data is presented as percentage increases or decreases in OCR and ECAR relative to baseline measurements. The baseline is shown as the blue line on the
graphs. B. Experiments were performed as described for A. using p53-null UM-SCC-1 cells and an isogenic derivative that stably expresses wild-type p53 from an integrated lentiviral
vector. C. Experiments were performed as described for A. using a wild-type p53 cell line UM-SCC-17A and an isogenic derivative stably expressing shRNA for p53. In each panel arrow 1
indicates increased respiratory capacity (OCR plot) or glycolytic reserve (ECAR plot) associated with wild-type p53 expression (whether endogenous or from a lentiviral vector) in contrast
with reduced respiratory capacity and glycolytic reserve highlighted by arrow 2 observed in p53 mutant, p53-null or p53 shRNA-expressing knock-down cells. Results presented are typical
from independent experiments performed on at least three occasions and similar data have been obtained by two individuals using both XF24 and XF96 instruments (MDW and EAA). (For
interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
phorylation and glycolysis respectively. Data were analysed using Wave
software (Seahorse Bioscience, Copenhagen. Denmark). During mito-
chondrial stress tests, inhibitors were injected sequentially as follows:
oligomycin 1.25 μM, FCCP 1.5 μM, and lastly a combination of rotenone
and antimycin-A 1 μM. During glycolytic stress tests, inhibitors were in-
jected sequentially as follows: glucose 10
mM, oligomycin 1.25 μM, and finally 2-DG 50 mM. ECAR was measured
in mpH/min.
To enable quantification and for comparison of OCR and ECAR
metabolic measurements between cell lines, normalisation to sample
DNA content was employed. The DNA content of samples following
completion of mitochondrial and glycolytic stress tests was determined
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Fig. 1. Continued
UK) and then DNA content was measured using a CyQUANT® cell pro-
liferation assay kit (Invitrogen, Paisley, UK), according to the manu-
facturer's instructions. Fluorescence was measured at 520 nm follow-
ing excitation at 508 nm using a POLARstar Omega plate reader (BMG
LABTECH, Ortenberg, Germany).
When analysing data between different cell lines non-parametric sta-
tistics were used due to the number of samples in each group (<30)
as per central limit theorem. Specifically, Mann-Whitney U tests were
utilised and the significance level for all tests was set at 0.05. For
the purposes of meaningful and valid comparison, statistical compar-
ison of absolute values for metabolic parameters was performed only
for isogenic cell lines (i.e. UM-SCC-17A versus UM-SCC-17A shp53 and
UM-SCC-1 and UM-SCC-1 wtp53), while analysis of relative levels of
basal glycolysis and mitochondrial respiration was performed for the re-
maining cell lines for which wild-type p53 and mutant p53 cell lines
were grouped together.
2.4. Cell viability and clonogenic survival assays
Cell viability was determined by trypan blue exclusion assays es-
sentially as described [30] and comparisons between treatment condi-
tions performed using Mann-Whitney U tests. To study radiation sen-
sitivity, we used clonogenic assays performed as described previously
[25,31]. Data were analysed as follows: the plating efficiency (PE)
was calculated from the 0 Gy conditions by dividing the number of
colonies formed by the number of cells seeded. The number of colonies
formed after treatment was then used to calculate the surviving fraction
(SF) for each treatment condition, accounting for the plating efficiency:
SF = (number of colonies formed/number of cells seeded) × PE. Sur-
vival parameters to generate treatment-dose survival curves for treat-
ment conditions were then derived from fitting the data by weighted,
stratified, linear regression according to the linear–quadratic formula
S(D) = exp(αD+βD [2]), where S is survival following a given dose (D)
of IR, which also allowed comparison between treatment conditions as
described by Franken et al. [31].
2.5. Flow cytometric quantitation of apoptosis and reactive oxygen species
Cells were analysed by flow cytometry using either a FACSCalibur™
instrument in which case data were analysed with CellQuest Pro Soft-
ware (both from BD Biosciences, Oxford, UK) or with an Attune®
acoustic focusing cytometer in which case data were analysed with At-
tune® Cytometric Software (both from Life Technologies, Paisley, UK).
Apoptosis was monitored using Annexin V and propidium iodide stain-
ing of cells and measured by flow cytometry essentially as described pre-
viously [32].
Reactive oxygen species (ROS) levels were monitored by flow cytom-
etry using the 2′,7′-dichloro-dihydro-fluorescein diacetate (DCFH-DA)
assay essentially as described [33].
Again, comparisons between treatment conditions performed using
Mann-Whitney U tests.
3. Results
3.1. TP53 status determines metabolic profile in SCCHN cells
We first investigated the metabolic profile of a panel of STR-vali-
dated SCCHN cell lines (Supplementary Data Table 1) to determine
the relative levels of glycolysis and oxidative phosphorylation/respira-
tion in these cells under standard growth conditions. We measured oxy-
gen consumption rate (OCR) as an indication of respiratory activity and
extracellular acidification rate (ECAR) as an indication of glycolysis us-
ing extracellular flux analysis. The results of these are shown in Fig. 1
and in Supplementary Data Fig. 2. The data clearly show that cells that
retain wild-type p53 (UM-SCC 17as, 17A, and 11A) retain extra respira-
tory capacity, whereas cells lacking wild-type p53 (UM-SCC-1, 5, 10A,
11B and 81B) operate either at or close to maximal respiratory levels
with little or no spare capacity. In addition, we observe in Fig. 1 (and
Supplementary Data Fig. 2), that cells harbouring wild-type p53 dis-
play greater glycolytic reserves generally than do cells that lack func-
tional p53 (UM-SCC 1, 5, 11B, 81B and to a lesser extent 10A [which
display a glycolytic reserve of ~30%]). Curiously the mutant cell line
that retains some unused glycolytic reserve (UM-SCC-10A) also fails to
completely respond to the inhibition of glycolysis leading to a reduc-
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Fig. 2. Continued
cose (UM-SCC-10A, Supplementary data Fig. 2B). The basis for this re-
mains unclear, but subsequent studies have identified a role for p53
in this phenotype that warrants further investigation (see below in dis-
cussion of Fig. 1C), and we have observed that there is a signifi-
cant (P < 0.01) increase in non-glycolytic acidification in mutant vs
wild-type cell lines as illustrated in Supplementary Data Fig. 3 B.
To further investigate the association between p53 status (nonsense
or missense mutant versus wild-type) and metabolic capacity/profile, we
next set out to examine whether the association of the observed meta-
bolic phenotypes with p53 status is due to a deterministic function of
p53.
As shown in Fig. 1B and C, functional studies identify that reintro-
ducing wild-type p53 into a p53-null cell line (UM-SCC-1) or compro
mising wild-type p53 function in a wild type p53 cell line
(UM-SCC-17A), leads to a predictable response that accords with the as-
sociation already observed. Specifically, Fig. 1B shows that in isogenic
derivatives of p53-null UM-SCC-1 that harbour wild-type p53 stably ex-
pressed from a lentiviral vector [16,34], both OCR and ECAR are trans-
formed in a dominant fashion that resembles the wild-type p53 cell line
profiles shown in Fig. 1A and in Supplementary Data Fig. 2. Similarly,
using RNAi to suppress wild-type p53 expression in UM-SCC 17A cells,
results in the reduced spare respiratory capacity and reduced glycolytic
reserve observed in p53 mutant cell lines (compare Fig. 1B with data
shown in Fig. 1A and B and Supplementary Data Fig. 2). Since ma-
nipulation of p53 robustly determines metabolic profile, we therefore
conclude that p53 can determine the metabolic profile in SCCHN cells
6
Metabolic profiling of head and neck cancer cells can dichotomise cells according to p53 status. Quantitative OCR and ECAR data, normalised to DNA content for cells expressing
wild-type p53 (blue), and mutant cells (red). Orange bars represent data from a p53 null cell line manipulated to express wild-type p53 and green bars derive from a p53 knock-down
wild-type cell line. As stated in the Methods, statistical comparison of absolute values for metabolic parameters was performed for isogenic cell lines (i.e. UM-SCC-17A versus
UM-SCC-17A shp53 and UM-SCC-1 and UM-SCC-1 wtp53), while analysis of relative levels of basal glycolysis and mitochondrial respiration was performed for the remaining cell lines
for which wild-type p53 and mutant p53 cell lines were assessed as groups as presented. A. displays data from mitochondrial stress tests with statistical analysis as follows: basal respira-
tion * P = 0.008 and **P = 0.004; ATP-linked respiration * P = 0.012 and **P < 0.001; maximal respiration * P = 0.004 and **P < 0.001; spare respiratory capacity * P < 0.001 and
**P < 0.001. B. displays data from glycolytic stress tests with statistical analysis as follows: basal glycolysis * P = 0.004 and **P < 0.001; glycolytic capacity * P = 0.012 and
**P = 0.022; glycolytic reserve * P = 0.028 and **P < 0.001. C. Plot of basal ECAR versus OCR dichotomises samples into p53 wild-type and p53 compromised (mutant/null/
knock-down) groupings. D. Additional studies performed using a Seahorse XF96 analyser and plotting basal ECAR/OCR as a ratio indicative of the Warburg effect: higher values are typi-
cal of normal cells with greater use of oxidative phosphorylation and lower values are typical of loss of normal p53 function, indicative of increased dependence on glycolysis. Grouped
cell lines harbouring mutant p53 demonstrated a significantly higher ratio of basal glycolysis to basal respiration (*P = 0.028). Direct comparison of the isogenic cell lines showed a sim-
ilar pattern (**P < 0.001 and ***P < 0.001). UM-SCC-17A lenti, is a UM-SCC-17A derivative that contains a lentiviral vector, UM-SCC-1 wtp53, is a UM-SCC-1 derivative that expresses
a wtp53 cDNA, UM-SCC-1 pBABE is a UM-SCC-1 derivative that contains the pBABE retroviral vector, and UM-SCC-17A shp53, is a UM-SCC-17A derivative that contains a lentiviral vec-
tor expressing a shRNA for p53. Results presented are typical from independent experiments performed on at least three occasions and similar data have been obtained by two individu-
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Fig. 3. Head and neck cancer cells with mutant TP53 display increased sensitivity to glycolytic inhibition with 2-DG. Viability of cells treated with the indicated compounds
was measured by trypan blue exclusion. A. and B. The indicated cell lines were exposed to either a no treatment vehicle control, 2-DG, UK5099 or a combination of 2-G + UK50099, as
indicated, for 48 h prior to staining. Values represent the mean from three separate experiments and error bars represent the standard error of the mean. In all cell lines with abrogation
of wtp53 function (either through mutation or knock-down) addition of 2-DG alone significantly reduced viability (*P < 0.01 in all cases), while in cell lines harbouring functional wtp53
both 2-DG and UK5099 were required to significantly reduced viability (**P < 0.01 in all cases). (For interpretation of the references to colour in this figure legend, the reader is referred
to the Web version of this article.)
and that loss of p53 function leads to a Warburg type profile displaying
greater apparent dependence on glycolysis and reduced respiratory ca-
pacity [15,35,36].
3.2. p53 suppresses glycolysis and promotes increased respiration
p53 status might impact upon metabolism in several ways, and
whilst the studies depicted in Fig. 1 and Supplementary Data Fig.
2 indicate a role for p53 in regulating the relative levels of glycolysis
and respiration, we wanted to determine whether the relative changes
in capacity are due to an actual increase or decrease in the cells capac
ity for glycolysis or oxidative phosphorylation, or due to changes in
both. To achieve this we used sample normalisation by DNA content to
perform similar experiments in a more quantitative manner. As Fig. 2A
illustrates, basal respiration, ATP-linked respiration and maximal respi-
ration are all lower in p53 mutant cells cf. wild-type cells. Moreover, re-
verse genetic experiments in isogenic cell lines in which wild-type p53
is introduced (UM-SCC 1 wt p53) or suppressed (UM-SCC 17A shp53)
mirror this phenotype.
Since mutant p53 cell lines have a lower respiratory activity, and
since respiration is a more energetically efficient process than glycoly-
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tory activity because they are operating at close to their maximal avail-
able respiratory capacity. As Fig. 2A shows, this is indeed the case.
In contrast, p53 wild-type cells display substantial spare respiratory ca-
pacity as well as higher absolute levels of respiration. In Fig. 2B, we
can see that both the absolute basal levels of glycolysis and total gly-
colytic capacity of these cells are substantially higher in SCCHN cells
that have compromised p53 function (harbouring variously null, mutant
or a knock-down of p53) than in p53-wild-type cells. These p53-compro-
mised cells also display greatly reduced glycolytic reserve capacity, and
as Fig. 2C shows, combining analysis of measurements of glycolysis and
of respiratory activity provides a means to dichotomise cells based upon
their metabolic activity that ultimately also predicts their TP53 status.
In further experiments shown in Fig. 2D the “Warburg effect” or phe-
notype is indicated by ascribing to each cell line a value derived from
the ratio of basal glycolysis/basal respiration (raw data for these exper-
iments are presented in Supplementary Data Fig. 3). This results in
clear dichotomisation of cells into p53 wild-type and p53 compromised
groups.
3.3. Loss of TP53 function leads to increased glycolytic dependence and a
Warburg phenotype
Following from the results presented in Fig. 2, it would be expected
that SCCHN cells in which p53 is compromised will be more dependent
upon glycolysis, and due to their reduced spare glycolytic capacity, will
therefore be more sensitive to inhibition of glycolysis than p53 wild-type
cells. If this was found to be correct, then therapeutic strategies could
be envisaged that would take advantage of the anticipated metabolic
sensitivity created by this oncogenic adaptation. To examine whether
p53-compromised cells do indeed have a greater dependence on glycol-
ysis, we measured the viability of cells in the presence and absence of
the glycolysis inhibitor 2-deoxy-d-glucose (2-DG) and the mitochondr-
ial pyruvate carrier (MPC) inhibitor UK5099, which directly inhibits the
TCA cycle and thus ultimately deprives the electron transport chain of
essential intermediates [37]. Fig. 3 demonstrates that cells harbouring
mutant p53 are sensitive to 2-DG alone, but not to UK5099 when used as
solo agents, whereas p53 wild-type cells display little sensitivity to inhi-
bition of glycolysis alone with 2-DG, but are, as expected, more sensitive
to UK5099. In both mutant and wild-type cells the combination of 2-DG
with UK5099 displayed little or no further impact on viability as might
be expected since in each class of cells one or other inhibitor is targeting
the primary energy generating pathway, glycolysis in the mutant cells
and respiration in p53-wild-type cells. Critically, in UM-SCC 1 cells (p53
null), that express wild-type p53 (UM-SCC 1 wtp53), the inhibition of vi-
ability induced by treatment with 2-DG is lost, and the cells also become
sensitive to UK5099, thus indicating the deterministic nature of p53 ex-
pression upon these phenotypes (Fig. 3). Conversely, down-regulation
of wild-type p53 by RNAi (UM SCC 17A shp53), leads to loss of sensi-
tivity to UK5099 and increased sensitivity to 2-DG compared to parental
p53 wild-type UM-SCC 17A cells (Fig. 3A).
It is well documented that not all TP53 mutations have the same
functional or phenotypic impacts [3,34,38]. Therefore we examined the
impact of inhibiting glycolysis or respiration in isogenic derivatives of
the UM-SCC 1 line that express different mutations of TP53 which oc-
cur frequently in SCCHN, two structural mutants R175H and C176F and
a contact mutant R282W [39]. Results presented in Fig. 3B show that
expression of any of these p53 mutants results in comparable metabolic
dependencies to the parental p53 null UM-SCC 1 line in contrast to the
same cells expressing wild-type p53 (UM-SCC 1 wtp53).
These results demonstrate that expression of wild-type p53 deter-
mines the balance of the metabolic processes in SCCHN cells leading to
increased dependence on respiration and less dependence on glycoly
sis and thus loss of p53 function through mutation or down-regulation
promotes a Warburg phenotype.
3.4. Inhibition of glycolytic flux radiosensitises SCCHN cells that harbour
mutant, but not wild-type p53
External beam radiation therapy (EBRT) is a mainstay of treatment
for SCCHNs either used as a primary treatment modality or as adjuvant
treatment in combination with chemotherapy [40,41]. Cell killing by
radiation is essentially an oxygen-dependent process [42,43] and one
of the major by-products of respiration are a variety of reactive oxygen
species (ROS). Because of the importance of p53 mutations and loss of
p53 function being linked with poor outcomes in SCCHN [3], we con-
sidered the possibility that inhibiting glycolysis would potentiate radi-
ation sensitivity in p53 mutant cells as a result of their increased de-
pendence on glycolysis. As shown in Fig. 4A, addition of 2-DG to cells
1 h prior to irradiation significantly potentiates the suppression of viable
colony growth in p53 mutant cell lines, but not in less glycolysis-depen-
dent p53-wild-type cells, as anticipated from the above metabolic stud-
ies. The data presented in Fig. 4B again confirm the deterministic na-
ture of p53 in these responses being based on isogenic cell lines in which
wild-type p53 is either down-regulated (UM-SCC 17A shp53) or re-in-
troduced into a p53 null background (UM-SCC 1 wtp53). Whilst 2-DG is
primarily an inhibitor of glycolysis, it is well documented to have addi-
tional effects that are not due to inhibition of glucose catabolism [44].
As with many drugs, whilst the mechanism of action may be unclear
(metformin is a good example of this), the therapeutic benefits remain
undisputed and in the case of 2-DG there remain good arguments for us-
ing it as a part of a potential cancer therapy, particular as a chemo-radi-
ation combination approach [45]. We have performed similar studies of
the radiation sensitising effect of another inhibitor of glycolysis (3-bro-
mopyruvate [3-BP]) and have obtained similar results as Supplemen-
tary Data Fig. 5 demonstrates. Again, there are concerns regarding the
specificity of 3-BP, it is certainly an alkylating agent with a number of
substrates, nevertheless, it is also clearly an inhibitor of glycolysis [46].
These results suggest that inhibition of glycolysis could be used to
augment the effectiveness of radiation for patients with tumours har-
bouring p53 mutations. In Fig. 5A, we show examples of flow cyto-
metric analysis of apoptosis using Annexin V/propidium iodide staining
in a wild-type p53 (UM-SCC 17as) and a mutant p53 line (UM-SCC-5)
which shows that IR+2-DG increases apoptosis in p53 mutant but not
in p53-wild-type cells. Further support for this is summarised in Fig.
5B which provides additional evidence that p53 has a deterministic role
in this process in isogenic cell lines (see also Supplementary Data
Fig. 4 and Supplementary Data Tables 2 and 3). As might be an-
ticipated from the data shown in Figs. 4 and 5B shows that p53 sta-
tus also distinguishes cellular responses to radiation-induced apoptosis
with p53 mutant cells displaying the highest increases in apoptosis re-
sulting from the addition of 2-DG treatment prior to exposure to IR
and wild-type displaying little or no additional apoptosis when glycol-
ysis is inhibited with 2-DG prior to IR. These results are reminiscent
of the earlier ECAR and OCR dichotomisation and place the same sam-
ples into two identical groupings as shown in Fig. 2C and D. An impor-
tant additional point that arises from these data relates to the toxicity
of 2-DG. Analysis of apoptosis using Annexin V indicates that exposure
of these cells to 2-DG alone, used at 25 mM (for all experiments), and
applied for 24 h for these experiments, in contrast to the 1 h treatment
used for the clonogenic assay experiments, increases Annexin V positiv-
ity by an average of 3–4% (3.74 ± 0.9% for wild type and 3.1 ± 0.6%
for mutant cell lines [mean ± SEM]) in the absence of radiation in
both wild-type and p53 mutant cells (see Fig. 5 and Supplementary
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Fig. 4. Head and neck cancer cells harbouring mutant p53 or with knocked-down p53 are sensitised to ionizing radiation by inhibition of glycolysis. Clonogenic assays demon-
strate that the presence of wild-type p53 (endogenous or expressed from an integrated lentiviral vector) suppresses the increased radio-sensitivity induced by inhibition of glycolysis. Cell
lines, as indicated, were plated and the next day were treated with vehicle or with the glycolytic inhibitor 2-DG for one hour prior to exposure to the indicated radiation dose. Survival
data were fitted to the standard linear quadratic equation S(D) = exp(αD+βD [2]) as described previously [25]. Results represent mean values obtained from at least three separate
experiments and error bars represent the standard error of the mean. P values were calculated according to the method described by Franken [31].
or less is likely to have little effect on cell viability in the absence of ra-
diation.
3.5. Radiosensitisation of SCCHN cells harbouring mutant TP53 is mediated
by ROS
Since inhibition of glycolysis rendered p53 mutant cells more sen-
sitive to radiation, and since radiation acts in an oxygen-dependent
manner to kill cells, we therefore investigated the role of ROS in this
process. Specifically, we investigated whether the increased radia
tion sensitivity displayed by p53 mutant SCCHN cells treated with 2-DG
to inhibit glycolysis could be abrogated by adding N-acetyl cysteine
(NAC) to augment cellular reducing capacity [47]. Fig. 6A demon-
strates that adding NAC completely rescues the increase in radiation
sensitivity induced in p53 mutant cells by 2-DG. To further investi-
gate the relevance of ROS in mediating the observed effects, we used
a flow cytometric assay to quantitate ROS in cells under similar con-
ditions to those used in Fig. 6A. Fig. 6B shows that adding NAC
to cells that had been irradiated and treated with 2-DG (panel vi)
results in a dramatic decrease in the level of ROS detected, return-
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Fig. 5. The radiosensitisation of head and neck cancer cells with compromised p53 function correlates with radiation-induced apoptosis. A. Flow cytometry analysis of rep-
resentative p53 wild-type (UM-SCC-17as) and mutant (UM-SCC-5) cell lines treated as indicated with either no treatment, staurosporine as a positive control for detection of apoptosis
induction, ionising radiation (IR), 2-DG or a combination of IR plus 2-DG harvested 24 or 48 h later as indicated. In all plots the abscissa indicates Annexin V detection and the ordinate
is propidium iodide detection. Percentages represent Annexin V positivity. B. Summarises the results for similar experiments to those described in A. performed on the indicated cell lines.
As in Fig. 2, blue bars represent data from cell lines with wild-type p53, red bars represent data from cell lines that are either p53 null or harbouring mutant p53, orange bars represent
data from a p53 null cell line manipulated to express wild-type p53 and green bars derive from a p53 knock-down wild-type cell line. In all cell lines with abrogation of wtp53 function
(either through mutation or knock-down) addition of 2-DG to IR significantly increased the proportion of annexin V positive cells at either 24 or 48 h (*P < 0.01 in all cases), while in
cell lines harbouring functional wtp53 no significant increase was observed. Results presented are typical results from an independent experiment that has been repeated on at least three
occasions. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
parable to those detected in untreated cells (panel i). Similar results
were obtained for all p53 mutant cell lines as summarised in Supple-
mentary Data Tables 4 and 5. Note that in Fig. 6B panel iv, there
is no increase in ROS production in the presence of 2-DG alone, thus
cells are not producing more ROS, but the rescue of IR sensitisation with
NAC, shows that ROS that is produced is more cytotoxic. This suggests
that the increased radiotoxicity in the presence of 2-DG is due to a re-
duction in the capacity of the cell to neutralise ROS that are produced.
The rescue of this effect with NAC supports this conclusion.
We conclude that the increased sensitivity to IR resulting from the
inhibition of glycolysis with 2-DG in p53 mutant cells is due to the
reduced capacity of mutant cells to tolerate ROS and not a conse
quence of increased production of ROS when cells are prevented from
utilising glycolysis as an major source of energy.
4. Discussion
Previous studies in a number of different types of cancer cells have
identified a role for p53 as a regulator of a range of cellular processes
directly and indirectly contributing to the regulation of many different
metabolic pathways [48]. In head and neck cancer cells, a series of ex-
cellent studies from the Myers’ group have shown that cells expressing
lower levels of p53 protein displayed reduced metabolic diversity, with
an increased dependence on glucose which can form the basis for a ther-
apeutic strategy [49]. These studies have raised several critical ques-
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Fig. 5. Continued
termine metabolic changes in SCCHN cells, for example would re-intro-
duction of wild-type p53 re-establish metabolic flexibility and ii) in a
more quantitative sense, what is the impact of TP53 status on the ab-
solute, rather than relative, levels of respiratory and glycolytic metab-
olism? The present study provides answers to both of these questions.
Our data demonstrate that re-introduction of wild-type p53 can reverse
the metabolic adaptation of p53 null mutant cells (but note that this
does not mean that re-introducing wild-type p53 into cells expressing
dominant negative or gain of function mutants of p53 would have the
same effect). We also find that not only does the metabolic profile, i.e.
the relative levels of glycolysis and respiration change away from res-
piration towards glycolysis in cells that lack p53 activity, but also the
capacity for respiration is substantially reduced and at the same time,
mutant p53 cells display an increase in glycolytic capacity. Given the
relative inefficiency of glycolysis compared to respiration in generating
energy from glucose, this increase in glycolytic capacity is not sufficient
to compensate for the reduction in respiratory activity and so there must
be important adaptive advantages to the cells to drive such an energeti-
cally negative alteration. One explanation is the need for increased flux
through the pentose phosphate pathway to increase reducing agents and
to produce the NADPH required for macromolecular biosynthesis and
promote cell survival in cells stressed by oncogenic events [50]. Regard-
less of the answer to such questions relating to the pressures that tumour
cells experience and adapt to, our data indicate that the metabolic bal-
ance and activity of individual metabolic processes is determined by the
TP53 status of cells.
Because of the critical role of radiation therapy in head and neck
cancer treatment, we have also investigated the impact of TP53 status
on short-term and long-term cellular radiation responses (apoptosis and
clonogenicity respectively), and again find that there are distinct dif-
ferences that are determined by p53. Due to the decreased capacity of
p53 mutant cells for respiration, mutant cells depend more on glycoly-
sis for energy production. We have found that this renders these cells
more sensitive to IR in the presence of inhibitors of glycolysis such as
2-DG. Our results suggest that this is due to decrease in the reducing
capacity of p53 mutant cells revealed by a short (1 h) exposure to a
glycolytic inhibitor. Most importantly, this radiosensitisation of mutant
p53 tumour cells by transient exposure to a glycolytic inhibitor should
be therapeutically achievable, requiring a similar approach to that be
ing used for the dosing of patients in the NIMRAD trial with nimorazole
90 min prior to irradiation [51]. We propose that future studies should
investigate the combinatorial therapeutic potential of augmenting radi-
ation therapy by administering a glycolytic inhibitor in a similar regime
to that used for nimorazole prior to delivering each fraction of radiation
in patients stratified by their TP53 status.
Our data suggest that either p53 mutant cells produce more ROS in
response to IR than p53 wild-type cells when glycolysis is inhibited or
they are more sensitive to the ROS produced than wild-type cells (or a
combination of the two). We therefore investigated the mechanism of
this effect and found that in p53 mutant cells the addition of N-acetyl
cysteine exogenously to the cells can overcome the increased radiation
sensitivity in the presence of 2-DG as determined by either short-term
or long term indicators (apoptosis and clonogenicity respectively). Thus
we conclude that the increased sensitivity to IR in the presence of 2-DG
is due to limiting availability of reducing agents such as glutathione that
can reduce ROS. Although this effect could still be due to p53 mutant
cells having greater intrinsic sensitivity to ROS, it seems simpler to pro-
pose that increased glycolytic flux leads to a shortage of reducing capac-
ity. This would be expected in cells exhibiting high levels of glycolysis
due to the high rate of conversion of glucose 6-phosphate into fructose
6–phosphate thus depleting the substrate for the oxidative branch of the
pentose phosphate pathway [52].
It has been well-documented that loss of p53 function is generally
linked with poorer patient outcomes in a wide range of common can-
cers including breast [1] and of particular significance here, in SCCHN
[3,34,53]. Such a link immediately identifies p53 and more specifically
TP53 mutations as potential biomarkers either with prognostic utility
as published or as we will argue here as potential predictive biomark-
ers. Most efforts to take advantage of TP53 mutations for patient strat-
ification envisage one of two scenarios. Firstly, in patients that retain
wild-type p53 pharmacological means to increase the activity of p53
in tumour cells are conceived, such are the MDM2 and MDM4 antag-
onists. These were first developed in a credible form by Roche [54],
but which now have been developed by numerous companies, some of
which display a broader binding spectrum that includes both MDM2 and
MDM4 [55]. Two problems can be anticipated with such approaches.
One, that the strategy is limited, since it can be targeted only to pa-
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Fig. 6. Radiosensitisation in p53 mutant cells is due to production of reactive oxygen species (ROS). A. Data from a clonogenic assay demonstrating that the radiosensitisation
induced by inhibiting glycolysis can be rescued by adding N-acetylcysteine which acts to increase the levels of reduced glutathione. Results represent mean values obtained from at least
three separate experiments and error bars represent the standard error of the mean. P values were calculated according to the method described by Franken [31]. B. Flow cytometry
analysis of cells either untreated, or exposed to hydrogen peroxide, ionising radiation (IR), 2-DG or the indicated combinations and harvested 24 h later. Percentages indicate the percent
of events (cells) within the gated region, indicating the majority of the normal ROS level. ROS is measured in the FL1-H channel and is quantitated using 2′,7′-dichloro-dihydro-fluorescein
diacetate. See also Supplementary Data Tables 4 and 5 for additional flow cytometry data. In all cell lines with abrogation of wtp53 function (either through mutation or knock-down)
addition of 2-DG to IR resulted in a significant shift in fluorescence indicative of increased ROS (measured by the proportion of cells inside/outside the gated parameter) (*P < 0.05 in all
cases), while in cell lines harbouring functional wtp53 no significant increase was observed. Results presented are typical results from an independent experiment that has been repeated
on at least three occasions.
tion [56]. Two, that applying a strong selective pressure to tumour cells
that promotes selection for cells that harbour p53 mutations and thus
to escape/resistance. The second scenario, focuses on patients that har-
bour mutations that inactivate p53. For tumours with mutations in the
TP53 gene, several strategies have been developed to exploit this. Two
of the most common approaches aim either to reintroduce wild-type
p53 or to rescue mutant p53 function. Delivering wild-type p53 gen-
erally depends upon gene targeting, and for now at least, no mecha-
nism exists to achieve this in a tumour cell targeted or even somewhat
targeted manner. Rescuing mutant p53 function, is prone to the same
challenges as occur with other tumour suppressor proteins; there are
many different mutations, and these affect the protein folding and func
tion to differing degrees. Thus it is unlikely that any single agent could
rescue the functions of diverse mutant proteins. Despite the overwhelm-
ing evidence that recovery of mutational loss of diverse tumour suppres-
sor gene functions is potently tumour suppressive, such rescue is inher-
ently difficult to achieve for any tumour suppressor except in a complex
experimental system used for proof of principle [57]. One further strat-
egy that deserves mention, is the development of viruses that display
some selectivity for replication in TP53 mutant cells and indeed, sev-
eral have been developed that display such selectivity in vitro. However,
whilst some beneficial responses have been observed in patients in clini-
cal trials these were only observed in combination with other therapies,
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Our data support the conclusion that a more promising strategy can
be developed, that does not target p53 or mutations in TP53, but rather
exploits cellular adaptations to loss of p53 function. Moreover, since
cancer cells arise as a consequence of selection for adventitious muta-
tions, it seems that targeting a single gene or protein merely provides
a limited selective window, since escape from such selective pressures
seems relatively likely. A more robust selection that targets a pathway
adaptation, for example the metabolic adaptations studied here, must
be more difficult to escape from, since other pressures have forced the
tumour cells to adopt otherwise energetically lass favourable metabolic
processes. Moreover, since such adaptations are common to the many
and heterogeneous population of cells in the tumour, targeting such
processes will affect the whole of the population. Warburg brilliantly
anticipated this when he wrote in 1927: “The resistance of single tu-
mor cells is not to be compared with that of single normal cells, but
rather the tumor as a whole with the organism as a whole. An overpop-
ulated city is more sensitive to stoppage of food supply than a normally
populated city, even when the inhabitants can all endure hunger alike”
[15]. Of course, with the metabolic adaptations that tumour cells dis-
play, these cells are inherently more sensitive to “starvation”. Thus the
potential to exploit this adaptation for therapeutic effect seems partic-
ularly attractive and we argue that the studies presented here provide
evidence of the direct functional link between p53 status and tumour
metabolism in SCCHN cells that could be readily exploited by combin-
ing a glycolytic inhibitor with standard radiotherapy for patient benefit.
Future experiments in a pre-clinical model are clearly needed and war-
ranted to provide further evidence of proof of principle, and to develop
and refine a therapeutic strategy of the kind envisaged as a result of the
present studies.
An important aspect of these studies is that they demonstrate that
loss of p53 function, whether by loss of protein expression (for example
through a splice site mutation), missense mutation leading to variously
loss of function only, dominant negative activity (DNA), gain of function
(GOF) or through down-regulation of wild-type p53 using RNAi leads to
a Warburg-type phenotype and more specifically to a loss of metabolic
flexibility in SCCHN cells. This presents us with an opportunity for de-
veloping therapeutic interventions that focus on the metabolic changes,
that is not restricted to a specific type of p53 mutation, nor is it rendered
inappropriate in the presence of p53 GOF. Thus, these data suggest that
such an approach could lead to a novel therapeutic strategy that should
be widely applicable given the high prevalence for p53 mutations in SC-
CHN (CATG report ca. 80% in non-HPV disease [4]).
Most importantly, our results demonstrate that since TP53 mutation
or loss of function confers increased dependence on glycolysis and in-
creased sensitivity to ROS with the resulting increased effectiveness of
IR, the strategy identified provides for a more effective treatment ap-
proach for patients with mutations in TP53, precisely those that cur-
rently perform less well.
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